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Background: Neuregulin 1 (NRG1) and NMDARs play important roles in various neuronal functions including neural
development. NMDARs also promote many cellular events such as proliferation and survival of neuroblasts before
synapse formation. Although many recent studies have indicated that NRG1 regulates NMDAR function in cortical
neurons, the effect of NRG1 on NMDAR activation before synapse formation is not well studied.
Results: NRG1 induces activation of NMDAR subunit NR2B, and tropomyosin-related kinase receptor B (TrkB), the
receptor for BDNF via activation of phospholipase C-gamma (PLC-γ) in immature primary cortical neurons. Our
data using TrkB inhibitor (K252a), TrkB siRNA and TrkB−/− neurons demonstrated that TrkB inhibition suppresses
NRG1-induced NR2B activation in neurons. We found that NRG1 stimulation leads to GABAA receptor-mediated
TrkB activation. Co-immunoprecipitation and proximity ligase assay showed that TrkB interacts with ErbB4 (NRG1
receptor) and the TrkB-ErbB4 interaction was increased following NRG1 treatment. A significant reduction in
TrkB-ErbB4 interaction was observed in the prefrontal cortex of schizophrenia subjects. We found significant increase
in released BDNF levels following NRG1 treatment, which was inhibited by ErbB4 inhibitor, AG1478. In addition,
pretreatment with BDNF neutralizing antibody, but not control IgG abolished NRG1-induced increases in
phospho-TrkB and phospho-NR2B levels. Moreover, studies using TrkB mutants showed that intercellular domain
of TrkB is necessary for TrkB-ErbB4 interaction and NR2B activation.
Conclusions: BDNF/TrkB signaling plays an important role in the NRG1-stimulated NR2B regulation. These findings
could be of relevance to many neurodevelopmental disorders, as NRG1 and BDNF signaling pathways have been
implicated in autism and schizophrenia.
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Activation of NMDA type glutamate receptors (NMDARs)
facilitate a number of signaling pathways involved in neur-
onal development, learning, and memory [1]. The develop-
mentally regulated expression of NR2 subunits is a key
component to controlling normal development of synapses
[2]. Moreover, the NMDAR composition changes through
development, with NR2B dominating in immature neurons
[3]. Interestingly, prior to synapse formation, activation
of NMDARs promotes many cellular events including
proliferation and survival of neuroblasts [4]. However, the* Correspondence: apillai@gru.edu
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article, unless otherwise stated.regulatory mechanisms of NMDAR activation are less
investigated before synaptogenesis than during or after
synaptogenesis.
Although the roles of a number of brain-derived trophic
molecules have been implicated in neuroplasticity, recent
studies show that neuregulin 1 (NRG1) plays a major role
in neurodevelopment and pathophysiology of neuropsychi-
atric disorders [5]. NRG1 is a member of the neuregulin
family of four related genes (NRG1-4) and is synthesized as
a transmembrane protein, which then undergoes proteo-
lytic processing by both neuronal activity and inter-
action with its ErbB receptor, ErbB4 [6]. NRG1 is
widely expressed throughout development and adulthood,
and plays important roles in neural development in-
cluding neuron migration, axon projection, myelination,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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studies have found the role of NRG1 in the regulation of
glutamatergic signaling; in particular NR2B function [7-9].
In addition, PLCgamma/Ca2+ signaling is known to medi-
ate NRG1-induced NMDAR regulation in neurons [10].
However, the above studies have investigated the effects of
NRG1 on NR2B activation either in neuroblastoma cell
lines or in neurons after synaptogenesis. Moreover, NRG1
has been shown to promote excitatory synapse develop-
ment in GABAergic interneurons [11]. These studies indi-
cate that the effect of NRG1 on NR2B function in neurons
prior to synapse formation needs further investigation.
Brain derived neurotrophic factor (BDNF) is a neuro-
trophic molecule that plays very important roles in
neurodevelopment and adult brain plasticity [12]. It is
known that binding of BDNF to TrkB elicits various
intracellular signaling pathways, including phospholipase
Cγ (PLCγ), which mediate the neuroprotective effects of
BDNF [13]. Moreover, BDNF enhances NR2B mediated
synaptic transmission via activation of TrkB [14]. Inter-
estingly, postmortem studies have reported alterations in
BDNF, NRG1 and their receptors in prefrontal cortex of
schizophrenia subjects indicating their roles in the patho-
physiology of this disorder [15-17]. Moreover, accumulat-
ing evidence has suggested alterations in glutamatergic
transmission via NMDA receptors in schizophrenia [18].
Based on the above studies that both NRG1 and BDNF
regulate neural development, and NMDARs promotes
many neuronal functions before synaptogenesis, we hy-
pothesized that NRG1-induces NR2B activation in imma-
ture neurons from embryonic mouse cortex via BDNF/
TrkB dependent mechanism. We report that TrkB inhib-
ition suppressed NRG1-induced NR2B phosphorylation in
neurons. We found that the interaction between ErbB4
and TrkB plays an important role in NRG1 regulation
of NR2B.
Results
TrkB inhibition suppresses NRG1-induced NR2B phosphor-
ylation in primary cortical neurons
We first determined the effect of NRG1 on the activa-
tion of ErbB4, TrkB and NR2B in dissociated cortical
neurons before synapses are formed (DIV 4) [19]. Acute
administration of NRG1 increased ErbB4 phosphoryl-
ation at Tyr1284 in cortical neurons (Figure 1Ai and ii).
In addition, TrkB phosphorylation at Y816 was increased
as a result of NRG1 treatment (Figure 1Ai and iii). We
observed increased NR2B phosphorylation at Ser1303 in
neurons following NRG1 exposure (Figure 1Bi). Next,
we examined NRG1-induced NR2B phosphorylation in
cultured cortical neurons after exposure to K252a (a Trk
inhibitor). K252a (30 min) suppressed NRG1-induced
NR2B phosphorylation indicating that NR2B regulation by
NRG1 involved Trk receptor activity (Figure 1Bi and ii).Trk inhibition did not alter NRG1-induced ErbB4
activation (Figure 1Bi and iii). The specificity of the
phosphoErbB4 antibody was confirmed in neuronal
lysates by immunoprecipitation of ErbB4 followed by
immunoblotting with phosphoErbB4 or phosphoTrkB
antibody (Figure 1Biv). To verify the role of TrkB, we
used TrkB siRNA to silence TrkB expression in primary
cortical neurons (Figure 1C). The downregulation of TrkB
by TrkB siRNA abolished NRG1-induced NR2B phos-
phorylation (Figure 1D). As a negative control, a scram-
bled siRNA was used, which permitted NR2B activation
following NRG1 treatment. To validate the above results
further, we used primary cortical neurons from TrkB
knockout (TrkB−/−) mice. Embryonic cortical neurons
isolated at E16 from TrkB−/− and wild-type (WT) mice
were treated at DIV 4 with NRG1. NR2B activation was
abolished in TrkB−/− neurons (Figure 1E). These results
suggest that NRG1-induced NR2B phosphorylation occurs
via TrkB signaling.
BDNF mediates NR2B phosphorylation by NRG1
Since TrkB was found as a key mediator of NR2B
regulation by NRG1, the possible role of its ligand,
BDNF was investigated. We hypothesized that increase
in BDNF release following NRG1 treatment stimulates
NR2B phosphorylation. We found a significant increase in
TrkB phosphorylation in cultured cortical neurons follow-
ing NRG1 treatment, which was blocked by AG1478, the
ErbB4 kinase inhibitor (Figure 2A). Western blot analysis
of phosphoErbB4 confirmed the effectiveness of AG1478
in inhibiting ErbB4 phosphorylation (Figure 2Bi). Immu-
nofluorescence analysis of phosphoErbB4 and parvalbu-
min showed that NRG1 induced ErbB4 activation occurs
in GABAergic interneurons (Figure 2Bii). Also, immuno-
fluorescence data confirmed our western blot results that
NRG1-induced ErbB4 activation is not dependent on
TrkB activation status. Moreover, BDNF ELISA showed a
significant increase in released BDNF levels following
NRG1 treatment, which was inhibited by AG1478
(Figure 2Ci). In addition, pretreatment with BDNF neu-
tralizing antibody (1 μg/ml), but not control IgG abolished
NRG1-induced increases in phospho-TrkB (Figure 2Di
and ii) and phospho-NR2B (Figure 2Di and iii) levels. We
observed reduction in total TrkB levels in neurons treated
with BDNF neutralizing antibody as compared to control
IgG-treated neurons (Figure 2Di). The reduction in TrkB
levels might be due to the cellular response to the lack of
ligand (BDNF) in neurons treated with BDNF neutralizing
antibody. Overall, these results support the role of BDNF/
TrkB signaling in the regulation of NR2B phosphorylation
by NRG1 in neurons.
It has been shown that neuregulin can induce GABAA
receptor expression in neurons [20], and GABAA receptor
activation stimulates BDNF release in developing neurons
Figure 1 Inhibition of TrkB suppressed NRG1 induced activation of NR2B in primary cortical neurons. (Ai) Time dependent effect of
NRG1 on ErbB4 and TrkB receptor activation. NRG1 (5 nM) was applied at DIV4 for indicated time course. (Aii) pErbB4 values were normalized
against total ErbB4 levels and (Aiii) pTrkB values were normalized against total TrkB levels. Data represent mean ± SEM. (n = 3). *P < 0.01 vs
control (CON). (Bi) Trk inhibitor K252a blocks the stimulatory effect of NRG1 on NR2B activation, but not ErbB4 activation in cortical neurons.
Cortical neurons were pretreated with 100 nM K252a for 30 min, followed by NRG1 for 5 min. (Bii) Quantification of normalized pNR2B and (Biii)
pErbB4. Data represent mean ± SEM. (n = 5). *P < 0.01 vs control;
$P< 0.01 vs NRG1 treatment. (Biv) The specificity of the pErbB4 antibody was
tested in cortical neurons. Immunoprecipitation (IP) with the anti-ErbB4 antibody or control IgG antibody followed by blotting with the anti-pErbB4,
anti-pTrkB or anti-ErbB4 antibody was performed in neurons (DIV4) after NRG1 stimulation. (C) Endogenous TrkB was decreased after TrkB-siRNA
transfection compared to scrambled siRNA. siRNA was transfected 48 h before lysates were collected. Data represent mean ± SEM. (n = 3). *P < 0.05.
(D) NRG1-induced NR2B activation was reduced in TrkB-siRNA transfected cultures. Data represent mean ± SEM. (n = 3). *P < 0.05 vs scrambled siRNA
group; $P < 0.05 vs NRG1 treated scrambled siRNA group. (E) Immunoblotting analysis of NRG1-induced NR2B activation in primary cortical neurons
isolated from WT and TrkB−/− mice. Data represent mean ± SEM. (n = 3). *P < 0.05 vs WT control; $P < 0.05 vs WT NRG1 treatment.
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mediating NRG1-induced TrkB activation, we exam-
ined whether inhibition of GABAA receptor activity
could block the effect of NRG1 on TrkB phosphorylation.
We found a significant inhibition on NRG1-induced
BDNF release (Figure 2Ci) as well as TrkB phosphoryl-
ation (Figure 2E) in neurons pretreated with picrotoxin, a
GABAA receptor antagonist. However, treatment with a
GABA agonist, muscimol (50 μM) significantly increased
BDNF release (Figure 2Cii). Furthermore, although
calcium has been shown to mediate an important role
in BDNF release, chelating intracellular calcium by
BAPTA-AM did not inhibit NRG1-induced TrkB phos-
phorylation in neurons, indicating that calcium is not
a key mediator in NRG1-induced TrkB activation
(Figure 2F).PLCγ is involved NR2B phosphorylation by NRG1
PLCγ plays a key role in tyrosine kinase-mediated signal-
ing pathways. Moreover, NR2B is known to bind to the
SH domain of PLCγ facilitating NR2B phosphorylation
[22]. Therefore, we hypothesized that TrkB mediated
NRG1-induced NR2B phosphorylation requires PLCγ
activation. We found a significant increase in PLCγ acti-
vation (as determined by phosphorylation at Tyr783) in
cultured neurons following NRG1 treatment, which was
abolished by pretreatment with K252a (Figure 3A). More-
over, pre-treatment with PLCγ inhibitor U73122 dramatic-
ally reduced NRG1-stimulated PLCγ (Figure 3Bi and ii) as
well as NR2B (Figure 3Bi and iii) phosphorylation in
neurons suggesting a potential role of PLCγ in NRG1-
induced NR2B activation. The role of PLCγ was further
confirmed using PLCγ siRNA in primary cortical neurons
Figure 2 BDNF is involved in NR2B phosphorylation by NRG1. (A) NRG1-induced TrkB activation was reduced by pre-treatment with ErbB4
inhibitor, AG1478 (5 μM) for 20 min. The upper panel shows a representative autoradiogram of pTrkB and TrkB, and the lower panel represents
normalized pTrkB values. (Bi) Immunoblot analysis shows ErbB4 activation with NRG1, which was blocked by AG1478. The upper panel shows a
representative autoradiogram of pErbB4 and ErbB4, and the lower panel represents normalized pErbB4 values. (Bii) NRG1 induced activation of
ErbB4 was inhibited by AG1478, but not by K252a. Cortical neurons were treated with 5 μM AG1478, an inhibitor of ErbB4, or K252a, an inhibitor
of TrkB, for 20 min prior to the addition of NRG1. Neurons were fixed and stained with phospho-ErbB4 and parvalbumin (PV) antibodies, and
visualized with Cy3 (red) and Cy2 (green) coupled secondary antibodies, respectively. Scale bar, 20 μm. (Ci) NRG1-induced increase in BDNF levels
in culture medium was blocked by pre-treatment of AG1478 or Picrotoxin (100 μM; 30 min pre-treatment). (Cii) GABA agonist, muscimol (50 μM;
30 min pre-treatment) increased BDNF levels in culture medium. (Di) Immunoblot analysis of NRG1-induced activation of TrkB and NR2B, in
presence of BDNF neutralizing antibody (1 μg/ml) or control IgG antibody pre-treated for 30 min. Quantification of (Dii) pTrkB and (Diii) pNR2B
showed a significant reduction in their levels with BDNF neutralizing antibody. (E) Inhibition of GABAA receptor activity with Picrotoxin suppresses
NRG1-induced activation of TrkB. The upper panel shows a representative autoradiogram of pTrkB and TrkB, and the lower panel represents
normalized pTrkB values. (F) Chelating intracellular Ca2+ with BAPTA-AM (50 μM) has no effect on NRG1-induced activation of TrkB. Data
represent mean ± SEM. (n = 3). *P < 0.05 vs WT control; $P < 0.05 vs WT NRG1 treatment.
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siRNA abolished NRG1-induced NR2B phosphorylation
as compared to scrambled siRNA (Figure 3Cii). Since we
did not find any significant effect of BAPTA-AM on
NRG1-induced TrkB phosphorylation in neurons, we
examined the role of atypical PKC species in the above
experiment. We found that NRG1 treatment induced
phosphorylation of PKCzeta, an atypical PKC species in
primary cortical neurons, and the above effect was inhib-
ited by pretreatment with K252a (Figure 3D).TrkB-ErbB4 interaction is involved in NR2B activation by NRG1
To understand the mechanism via which TrkB controls
NRG1-induced NR2B phosphorylation, the endogenous
levels of TrkB and ErbB4 after NRG1 treatment was ex-
amined. No change in the above proteins was found in
the western blot analysis (Figure 1Ai). Next, the possible
interaction between ErbB4 and TrkB was investigated in
neurons following NRG1 exposure. Following immuno-
precipitation with anti-TrkB antibody, coprecipitated
ErbB4 was found in neuronal lysates (Figure 4A). NRG1
Figure 3 PLCγ mediates NR2B activation by NRG1. (A) NRG1-induced PLCγ activation is TrkB dependent. The upper panel shows a representative
autoradiogram of pPLCγ and PLCγ, and the lower panel represents normalized pPLCγ values. (Bi) Immunoblot analysis of NRG1-induced activation of
PLCγ and NR2B in presence of U73122. U73122 inhibited NRG1-increased phosphorylation of (Bii) PLCγ and (Biii) NR2B. Data represent mean ± SEM.
(n = 5). *P < 0.05 vs control; $P < 0.05 vs NRG1 treatment. (Ci) Endogenous PLCγ was decreased after PLCγ siRNA transfection compared to scrambled
siRNA. The upper panel shows a representative autoradiogram of PLCγ and β-actin, and the lower panel represents normalized PLCγ values. Data
represent mean ± SEM. (n = 3). *P < 0.05. (Cii) NRG1-induced NR2B activation was reduced in PLCγ siRNA transfected cultures. The upper panel shows
a representative autoradiogram of pNR2B and NR2B, and the lower panel represents normalized pNR2B values. Data represent mean ± SEM. (n = 3).
*P < 0.05 vs scrambled siRNA group; $P < 0.05 vs NRG1 treated scrambled siRNA group. (D) Immunoblotting analysis of NRG1-induced PKCzeta
activation in isolated primary cortical neurons. The upper panel shows a representative autoradiogram of pPKCzeta and PKCzeta, and the lower panel
represents normalized pPKCzeta values. Data represent mean ± SEM. (n = 3). *P < 0.05 vs control; $P < 0.05 vs NRG1 treatment.
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whereas pretreatment with K252a abolished the inter-
action. Reverse immunoprecipitation also showed similar
results (Figure 4B). In addition, pretreatment with BDNF
neutralizing antibody abolished NRG1-induced increases
in TrkB-ErbB4 complex formation (Figure 4C). The inter-
action between TrkB and ErbB4 was further confirmed by
PLA. The PLA identifies interaction between two proteins
in their native form and results in a fluorescent signal
in the form of a spot when the two proteins of inter-
est are closer than 40 nm. There was a significant
increase in PLA signal in NRG1-stimulated neurons
compared with unstimulated cells (Figure 4Di and ii).
Taken together, these results indicate that NRG1-induced
increase in TrkB-ErbB4 complex depends on BDNF/TrkB
signaling.
The intracellular domain of TrkB Contributes to
ErbB4-TrkB interaction
The observed role of TrkB phosphorylation in NRG1-
induced NR2B activation suggested an intracellular con-
tribution to TrkB-ErbB4 interaction. Blockade of TrkBphosphorylation may inhibit receptor internalization as
TrkB phosphorylation is needed for TrkB internalization
[23]. To examine whether the intracellular domain of
TrkB is involved in TrkB-ErbB4 interaction, mutant of
TrkB lacking the intracellular domain (TrkB Δ ICD)
was used. The transfection efficiency was determined
by quantification of the percentage of GFP-positive cells
relative to all cells in the culture. We found 30-40% trans-
fection efficiency in our experiments. The activity of TrkB
Δ ICD was confirmed in cultured cortical neurons. Treat-
ment of neurons with BDNF stimulated TrkB activity in
neurons expressing full length TrkB, but not in neurons
transfected with TrkB Δ ICD (Figure 5A). In addition, we
did not find any significant increase in NR2B activation in
neurons transfected with TrkB Δ ICD (Figure 5B). To find
out whether TrkB intracellular domain is necessary for
NRG1-induced interaction between TrkB and ErbB4, we
transfected neurons with TrkB Δ ICD. NRG1-induced in-
crease in TrkB-ErbB4 interaction was inhibited in neurons
expressing TrkB Δ ICD indicating the role of intracellular
domain of TrkB in NRG1-induced TrkB-ErbB4 inter-
action (Figure 5C).
Figure 4 TrkB-ErbB4 interaction was increased following NRG1 treatment. (A) Immunoprecipitation (IP) with the anti-TrkB antibody or
control IgG antibody followed by blotting with the anti-ErbB4 or anti-TrkB antibody was performed in neurons (DIV4) after NRG1 stimulation with
or without K252a pretreatment. (B) IP with the anti-ErbB4 antibody or control IgG antibody followed by blotting with the anti-TrkB or anti-ErbB4
antibody. (C) Inhibition of NRG1-induced increase in TrkB-ErbB4 interaction in neurons (DIV4) with a BDNF neutralizing antibody. The upper panel
shows a representative autoradiogram of TrkB and ErbB4, and the lower panel represents normalized TrkB values. Data represent mean ± SEM.
(n = 3). *P < 0.05 vs control; $P < 0.05 vs NRG1 treatment. (Di) PLA was performed in DIV4 cortical neurons following treatment with NRG1 for
5 min. The antibodies were omitted in the control PLA group (control PLA). The images were acquired at 20X or 40X and scale bar is 20 μM. The
red spots represent the interaction between TrkB and ErbB4. (Dii) Quantitation of PLA signal was performed in three independent experiments
using imageJ. Data represents mean PLA signal/cell ± SEM. *P < 0.05 vs control.
Figure 5 Intracellular domain of TrkB was required for NRG1 induced NR2B activation. (A) BDNF treatment increased TrkB activation in
cortical neurons transfected with full-length TrkB (TrkB-FL), but not in neurons transfected with TrkB lacking intracellular domain (TrkB Δ ICD). The
upper panel shows a representative autoradiogram of pTrkB and TrkB, and the lower panel represents normalized pTrkB values. Data represent
mean ± SEM. (n = 3). *P < 0.05 vs control; $P < 0.05 vs BDNF treatment (B) NRG1 failed to activate NR2B in neurons transfected with TrkB Δ ICD.
The upper panel shows a representative autoradiogram of pNR2B and NR2B, and the lower panel represents normalized pNR2B values. Results
are mean ± SEM. (n = 3) *P < 0.05 vs TrkB-FL; $P < 0.05 vs NRG1 + TrkB-FL. (C) Immunoprecipitation (IP) with the anti-TrkB antibody or control IgG
antibody followed by blotting with the anti-ErbB4 or anti-TrkB antibody was performed in NRG1-treated cortical neurons transfected with TrkB
lacking intracellular domain (TrkB Δ ICD).
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of schizophrenia subjects
Since both BDNF and NRG1 are implicated in the
pathophysiology of schizophrenia, we examined whether
the interaction between TrkB and ErbB4 is altered in
schizophrenia. Following immunoprecipitation with TrkB,
prefrontal cortical lysates from schizophrenia and control
subjects were examined for ErbB4 levels. We found a de-
crease in TrkB/ErbB4 interaction in the prefrontal cortex of
schizophrenia subjects as compared to controls (Figure 6A).
In addition, we found a significant reduction in TrkB pro-
tein levels in the prefrontal cortex of schizophrenia subjects
(Figure 6B).
Discussion
We have shown that TrkB inhibition suppressed NRG1-
stimulated NR2B phosphorylation via PLC signaling in
cortical neurons before synaptogenesis. NRG1 treatment
increased BDNF release from neurons and a BDNF-neu-
tralizing antibody inhibited NRG1-induced NR2B acti-
vation. TrkB interacted with ErbB4 in neurons and the
NRG1-induced increase in TrkB-ErbB4 interaction was
decreased following TrkB inhibition.
Our data illustrate the interaction between two signaling
pathways (BDNF and NRG1), which are well studied for
their roles in synaptic plasticity and in the pathophysiology
of many neuropsychiatric disorders including schizophre-
nia. Previously, independent studies have shown that both
NRG1 and BDNF activate NR2B signaling in cortical neu-
rons during or after synaptogenesis [7,24]. We now showFigure 6 Decrease in TrkB-ErbB4 interaction in the prefrontal cortex o
anti-TrkB antibody followed by blotting with the anti-ErbB4 or anti-TrkB wa
schizophrenia (N = 15) subjects. Representative immunoblots and quantifica
levels in the prefrontal cortex of schizophrenia subjects as determined by w
representative autoradiogram of TrkB and β-tubulin, and the lower panel re
for schizophrenia and N = 15 for control subjects). *P < 0.05 vs controls.that TrkB is essential for NRG1 to activate NR2B in neu-
rons before synaptogenesis. It has been shown previously
that NRG1 activates ErbB4 and its interaction with PLCγ
in neurons [25], and NR2B has been shown to bind
to the SH domains of PLCγ [22]. Thus, PLCγ is probably
the mediator of NRG1-induced NR2B phosphorylation
in neurons. This conclusion is strongly supported by
the present findings showing a robust reduction in
phosphoNR2B levels when PLCγ activity was inhibited
in NRG1-treated cells.
NRG1 acutely activates NR2B phosphorylation via
activation of ErbB4 in neurons [7]. The loss of TrkB
function results in the reduction in NR2B activation
following NRG1 exposure and that this is caused by
alterations in BDNF levels. Thus, it is possible that the
activation of ErbB4 by NRG1 contributes to NR2B phos-
phorylation by inducing the GABAAR-mediated release of
BDNF from neurons, which then act on TrkB-expressing
neurons promoting NR2B activation via PLCγ (Figure 7).
It has been shown that ErbB4 signaling regulates BDNF
expression, and the loss of ErbB4 signaling results in
reduced BDNF expression in mice [26]. The lack of effect
of BAPTA-AM on NRG1-induced TrkB phosphorylation
suggests that NRG1 induces TrkB activation via calcium
independent process. It has been previously shown that
BDNF/TrkB signaling induces CREB phosphorylation in
cortical neurons via MAP kinase pathway, but not
through calcium-dependent process [27,28]. Although
inhibition of BDNF function suppresses NRG1-induced
NR2B phosphorylation, the cellular localization of thef schizophrenia subjects. (A) Immunoprecipitation (IP) with the
s performed in prefrontal cortex samples from control (N = 15) and
tion of normalized ErbB4 are shown. (B) Decrease in TrkB protein
estern blotting with anti-TrkB antibody. The upper panel shows a
presents normalized TrkB values. Data represent mean ± SEM. (N = 15
Figure 7 BDNF/TrkB signaling regulates NR2B phosphorylation by NRG1 in immature cortical neurons. NRG1-induced activation of its
receptor ErbB4 on GABAergic interneurons results in an increased release of GABA. GABAAR activation, possibly via an autocrine manner in
immature neurons leads to release of BDNF, and stimulation of signaling cascades, including TrkB and PLCγ. This leads to the activation of NR2B,
providing the machinery required for various neuronal functions before synaptogenesis. Whether NRG1-induced GABAAR activation occurs in
mature cortical neurons via autocrine and/or paracrine manner needs further investigation. In the brain, NRG1 [32] and BDNF [12] are primarily
expressed in neurons and astrocytes in vivo.
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[29] and TrkB [30] are mostly expressed in parvalbumin
(PV)-positive interneurons. Moreover, NMDARs expressed
by the PV-positive fast spiking interneurons play a funda-
mental role in the maintenance of normal GABAergic
function, and NMDAR hypofunction in PV neurons resul-
ted in many behavioral and neurochemical abnormalities
in mice homologous to schizophrenia [31].
We found a robust increase in TrkB-ErbB4 interaction
following NRG1 treatment, which was suppressed by
TrkB inhibition. It is possible that TrkB activation is
necessary for the interaction of TrkB with ErbB4. Fur-
thermore, the intracellular domain of TrkB is required
for ErbB4 interaction. A significant reduction in TrkB-
ErbB4 interaction found in the prefrontal cortex of
schizophrenia subjects could be due to the decrease in
TrkB expression previously reported in this brain region
of schizophrenia subjects (17). We found that NRG1
treatment stimulates TrkB phosphorylation in neurons,
which was inhibited by a BDNF neutralizing antibody,
and BDNF inhibition abolished NRG1-induced increase
in TrkB-ErbB4 interaction. NRG1-induced ErbB4 activa-
tion is known to increase GABA release [33]. Our findings
indicate that GABAAR activation could be a possible
mechanism for NRG1-induced increase in BDNF/TrkB
signaling.
Both NRG1 and BDNF play important role in neuro-
development and synaptic plasticity. Since NRG1 and
BDNF are also present in non-neuronal cells such as
oligodendrocytes and astrocytes, it is important to iden-
tify whether the processes similar to the ones found
in the current study are functioning in those cell types.
Moreover, it will be interesting to examine whether TrkB-
ErbB4 interaction plays any role in GABAergic function in
interneurons. The signaling mechanism described in thisstudy, in which the regulation of NR2B activation by
NRG1 is mediated by BDNF/TrkB signaling, may function
in developing neural networks to enable NRG1 to modu-
late synaptogenesis, and growth of dendrites and axons
prior to the formation of functional synapses. It will also
be important to determine the extent to which this mech-
anism persists in the adult nervous system and contributes
to the regulation of synaptic plasticity and cognitive
function by NRG1 and BDNF. Given the alterations
in NRG1 and BDNF signaling pathways result in neuronal
dysfunctions as well as the implication of NMDARs in
neuroplasticity, our findings on the role of TrkB in NRG1-
stimulated NR2B phosphorylation could be of relevance
to many neurodevelopmental disorders, as NRG1 and




Timed pregnant CD-1 mice were purchased from Charles
River Laboratories (Wilmington, MA, USA). TrkB knock-
out (C57BL/6; TrkB−/−) were provided by Dr. Barbara
Rohrer, Medical University of South Carolina, Charleston,
SC and the colony was maintained in our animal housing
facility at the Georgia Regents University. All experiments
were done in compliance with Georgia Regents University
animal welfare guidelines.
Time pregnancy and genotyping
TrkB−/− mice were bred on C57BL/6 backgrounds and
their offspring were genotyped at embryonic day 16
(E16) by PCR of tail biopsy DNA (DNeasy kits; Qiagen).
PCR reaction was performed over 35 cycles using GoTaq®
Green Master Mix (Promega). Primers utilized were as
follows: trkb-n2: 5′-ATGTCGCCCTGGCTGAAGTG;
Pandya and Pillai Cell Communication and Signaling 2014, 12:47 Page 9 of 11
http://www.biosignaling.com/content/12/1/47trkbc8: 5′-ACTGACATCCGTAAGCCAGT; pgk3-1: 5′-
GGTTCTAAGTACTGTGGTTTCC. Annealing temp-
erature was set at 60°C. The products of the PCR
reaction were visualized using agarose gel electrophoresis.
Cell culture
Primary cortical neurons were prepared at E16. Neurons
were cultured in Neurobasal medium containing, B27 sup-
plement, 10% Fetal Bovine Serum (FBS), penicillin/strepto-
mycin mixture of antibiotics and Glutamax for 4 days. The
following pharmacological treatments were used: Neu-
regulinβ1 (Prospec, Israel) at 5 nM [34]; the Trk inhibitor,
K252a (Tocris Biosciences, Minneapolis) at 100 nM; the
ErbB4 inhibitor, AG1478 (Tocris) at 5 μM; PLC inhibitor,
U73122 (Tocris) at 2 μM; BAPTA-AM (Tocris) at 50 μM;
mouse anti-BDNF neutralizing antibody (1 μg/ml) [35];
GABA agonist, muscimol (Tocris) at 50 μM and GABAA
receptor antagonist, picrotoxin (Tocris) at 100 μM. Inhibi-
tor, agonist or antagonist was added 20 or 30 min prior to
NRG1 treatment.
Immunoblotting
Cells were lysed in ice-cold radioimmununoprecipitation
assay (RIPA) buffer (Tecnova) containing 150 mM NaCl,
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
50 mM Tris–HCl (pH 7.5), 2 mM EDTA (pH 8.0),
5 mM NaF, 2 mM Na3VO4, 1% protease inhibitor cock-
tail (Sigma), and 1 mM phenylmethylsulfonyl fluoride.
The protein concentration was quantified using a BCA
Protein Assay Kit (Sigma). Equal amounts of protein
were resolved in SDS–polyacrylamide gels and transferred
electrophoretically onto a nitrocellulose membrane (Bio-
Rad). Blots were incubated with primary antibodies
overnight at 4°C. After washing with 1× PBS and
blocking with 5% milk in 1× PBS, blots were incu-
bated with HRP-conjugated anti-rabbit or anti-mouse
secondary antibody (Santa Cruz Biotechnology) for 1 h,
followed by developing with the ECL Plus Western Blot-
ting Detection System (GE Healthcare). Chemilumines-
cence signals were captured on autoradiographic blue
films (Bioexpress). Films were scanned and the densito-
metric values for the proteins of interest were corrected
using β-actin or β-tubulin with Image J Software (NIH).
Primary antibodies were used at the following dilutions:
anti-ErbB4 (1:1000, Cell Signaling), anti-pErbB4 (1:500,
Cell Signaling), anti-TrkB (1:1000, Cell Signaling), anti-
pTrkB (1:1000, kindly gifted by Dr Chao, New York Uni-
versity School of Medicine, New York) [36-38], anti-PLCγ
(1:500, Santa Cruz Biotechnology Inc.), anti-pPLCγ (1:500,
Cell Signaling), anti-PKC ζ (1:500, Santa Cruz Biotechnol-
ogy Inc.), anti-pPKC ζ (1:500, Cell Signaling), anti-NR2B
(1:500, Novus Biologicals), anti-pNR2B (1:500, Millipore),
anti-BDNF (1:200, Santa Cruz Biotechnology Inc.), anti-
βtubulin (1:5000, Cell Signaling) and anti-βactin (1:5000,Sigma). For immunoprecipitation, 300 μg of proteins were
pre-cleared for 1 h with 30 μl of PureProteome Protein A
and G Magnetic Beads (Millipore), followed by incubation
overnight at 4°C in the presence of the primary antibody.
The immunoprecipitated proteins were subjected to im-
munoblotting for the detection of the coprecipitated
protein.Immunofluorescence staining
For immunofluorescence staining of primary cortical
neurons, cultured neurons at DIV4 were permeabilized
5 min with 0.2% v/v triton-X100 and blocked for 1 hr at
room temperature with 5% normal donkey serum. Anti-
pErbB4 (1:1000) and anti-PV(1:2000; Swant) staining
was performed overnight at 4°C followed by rinsing with
PBS and incubation for 1 hr at room temperature with
Cy2 and Cy3 conjugated secondary antibodies (Jackson
Immunoresearch). Cells were then washed and mounted
using ProLong® Gold Antifade Mountant containing DAPI
(Molecular Probes). Images were taken using a LCM
confocal microscope (Zeiss).Duolink proximity ligation assay (PLA)
The PLA was performed using Duolink In Situ reagents
(Sigma). The cortical neurons (~2 × 104 cells/well) were
seeded into 24-well plate on poly-D-lysine coated cover
slip. After treatment, the cortical neurons were washed
twice with ice-cold 1 × PBS and fixed with 4% paraformal-
dehyde and 120 mM sucrose in PBS at room temperature
for 20 min. After permeabilization the cells were incubated
in the blocking buffer (provided with the kit) overnight at
37°C in a humidified chamber. The cells were incubated
with the primary antibodies, anti-TrkB (1:500, Cell Signal-
ing) and anti-ErbB4 (1:500, Cell Signaling) diluted in the
antibody diluents for 2 hours at room temperature followed
by washing in Buffer A (supplied with the kit) 3 times for
15 minutes and incubation with the PLA probes for one
hour at 37°C in a humid chamber. The antibodies were
omitted in the PLA control group. The cells were again
subjected to a 10 minute wash and a 5 minute wash in
Buffer A. The ligation reaction was carried out at 37°C for
one hour in a humid chamber followed by a 10 and 5 mi-
nute wash in Buffer A. The cells were then incubated with
the amplification-polymerase solution for two hours at
37°C in a darkened humidified chamber. After washing
with 1x Buffer B (supplied with the kit) for 10 minutes
followed by a 1 minute wash with 0.01X buffer B the cells
were mounted using the mounting media supplied with the
kit. Images were collected using Zen 2012 lite imaging
software from several fields of view per experiment. The
number of PLA signals per cell (indentified as red spots)
was counted from three Z-plane images using ImageJ
(NIH).
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Brain-derived neurotrophic factor was measured with a
conventional sandwich ELISA using the BDNF Emax
Immuno-Assay System (Promega, Madison, WI, USA)
according to the protocol of the manufacturer.TrkB deletion plasmids
pBiFC-TrkB-FL and pBiFC-TrkB-Δ-ICD constructs were
kindly provided by Dr Maruyama, Okinawa Institute of
Science and Technology, Japan [39]. These constructs
were transfected into primary cortical neurons using
Effectene Transfection Reagent (Qiagen) 48 h before
NRG1 treatment.Small interfering RNA (siRNA)
We used 19 nt siRNA (GCACAUAAAUUUCACACGA,
M-048017-01-0005) named Ntrk2 for mouse TrkB and
19 nt siRNA (GCAAGAAGUUCCUCCAGUA) for mouse
PLCγ (M-040978-01-0005) from Dharmacon Research Inc.
The mouse control siRNA used was 19 nt quadruplex with
two 3′ overhanging nucleotides (D-001206-13, Dharmacon
Research Inc.). Transfection of both siRNAs (50 nM) was
performed in cultured cortical neurons using Amaxa
4D-Nucleofector Protocol (Lonza) 48 h before the
NRG1 treatment.Postmortem samples
We obtained postmortem prefrontal cortex samples from
schizophrenia (N = 15) and control (N = 15) subjects from
the Human Brain and Spinal Fluid Resource Center (Los
Angeles, California, United States). Description on the
demographic details of samples is published elsewhere
[40]. The samples were shipped frozen and stored at −80°C
until analysis. Grey matter was removed from a 1.5–2.0 cm
thick coronal slab of the frontal cortex anterior to the
corpus callosum and the prefrontal cortex was dissected
[41]. Tissue was homogenized in a homogenizing buffer
containing 20 mM Tris–HCl (pH 7.4), 2 mM EGTA,
5 mM EDTA, 1.5 mM pepstatin, 2 mM leupeptin, 0.5 mM
phenylmethylsulfonyl fluoride, 0.2 U/ml aprotinin, and
2 mM dithiothreitol. The homogenate was centrifuged at
15,000 rpm for 15 min at 4°C. Protein concentration in the
supernatant was determined with BCA Reagent.Statistical analysis
Quantified data are presented as mean ± SEM and
analyzed by GraphPad PRISM. Statistical comparisons
between two groups were made using t tests. Comparisons
among multiple groups were made using one-way or two-
way ANOVA, with Bonferroni’s post hoc analyses to iden-
tify significant differences between groups. The probability
(p) values of less than 5% were considered significant.Competing interest
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